Hysteromyoma neoantigen and application thereof and hysteromyoma vaccine
A technology for uterine fibroids and vaccines, which is applied in the field of biomedicine to achieve the effect of preventing occurrence and recurrence, preventing recurrence and having good targeting.
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0031] Example 1 Neoantigen Binding Ability to Corresponding MHC
[0032] The affinity analysis software NetMHC software was used to analyze the binding ability of neoantigens shown in SEQ ID NO: 1 to 9 and their corresponding wild-type polypeptides to the corresponding major histocompatibility molecules (MHC), and the results are shown in Table 1 . The ability of a neoantigen to bind to the corresponding MHC is expressed by the minimum concentration of antigen polypeptide required to achieve stable MHC-antigen polypeptide binding. The lower the concentration (affinity value), the more stable the binding of the neoantigen to the MHC molecule, the stronger its antigenicity, and the better it can stimulate the proliferation of specific T cells.
[0033] Table 1 The binding ability of neoantigens and their corresponding wild-type polypeptides to corresponding MHC
[0034]
[0035]
[0036] It can be known from the results in Table 1 that the binding abilities of the neoan...
Embodiment 2
[0037] Synthesis of embodiment 2 neoantigen
[0038] The amino acid sequences of the nine neoantigens are shown in SEQ ID NO: 1 to 9, and were synthesized by GenScript Biotechnology Co., Ltd., with a purity greater than 99%, HPLC grade, and RNase-free.
Embodiment 3
[0039] Example 3 Synthesis of non-methylated oligodeoxynucleotides of full-thio-modified CpG-rich sequences
[0040] Select the agonist of TLR9--the non-methylated oligodeoxynucleotide with rich CpG sequence modified by all sulfur as one of the adjuvants of uterine leiomyoma vaccine, the unmethylated oligodeoxynucleoside with rich CpG sequence The nucleotide sequence of the acid is: 5'-TCGTCG TTT TGT CGT TTT GTC GTT GGG G-3' (SEQ ID NO: 10). Entrust GenScript Biotechnology Co., Ltd. to synthesize and fully thio-modify the non-methylated oligodeoxynucleotides of the CpG-rich sequence to obtain the fully-thio-modified non-methylated oligodeoxynucleotides of the CpG-rich sequence Acid, a synthesis of 21.8mg, approximately equal to 600OD.
PUM
Abstract
Description
Claims
Application Information
- R&D Engineer
- R&D Manager
- IP Professional
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com